Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Type: Journal article
Title: Assessing overall duration of cardiovascular medicines in veterans with established cardiovascular disease
Author: Roughead, E.
Vitry, A.
Preiss, A.
Barratt, J.
Gilbert, A.
Ryan, P.
Citation: European Journal of Cardiovascular Prevention ' Rehabilitation, 2010; 17(1):71-76
Publisher: Lippincott Williams & Wilkins
Issue Date: 2010
ISSN: 1741-8267
Statement of
Elizabeth E. Roughead, Agnes I. Vitry, Adrian Kym Preiss, John D. Barratt, Andrew L. Gilbert, Philip Ryan
Abstract: BACKGROUND: This study aimed to determine persistence, adherence, and time without therapy with cardiovascular medicines over all episodes of use among veterans following hospitalization for ischemic heart disease. METHODS: Retrospective cohort study using Department of Veterans' Affairs database including 9635 veterans with a hospitalization for acute myocardial infarction, angina, or ischemic heart disease, and who had been dispensed cardiovascular medicines in the 3 months posthospitalization. The main outcome measures were duration of first treatment episode, duration of overall treatment episode, and adherence with recommended therapies: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), lipid-lowering therapy, calcium channel blockers (CCBs), beta-blockers, and antiplatelet therapy. RESULTS: The median duration of overall treatment was 6.2 years [95% confidence interval (CI): 6.0-6.4] for lipid-lowering therapy, 5.4 years (95% CI: 5.1-5.5) for ACE inhibitors/ARBs, 5.0 years (95% CI: 4.8-5.1) for antiplatelets, 3.4 years (95% CI: 3.3-3.6) for beta-blockers, and 2.8 years (95% CI: 2.6-3.0) for CCBs. Adherence was 72% for CCBs, 75% for ACE inhibitors/ARBs, 84% for lipid-lowering therapy, and 84% for antiplatelets other than aspirin. The median time without therapy was 4.5 months or less for ACE inhibitors/ARBs, antiplatelets, and lipid-lowering therapy. CONCLUSION: Problems with medication adherence can relate to either persistence or compliance during treatment. This novel method provides a way to determine which of these factors is most problematic when considering chronic therapies. We found that Australian veterans with established cardiovascular disease are persistent with their cardiovascular therapy, with only small gaps in therapy.
Keywords: aged; cardiovascular drugs; medication adherence.
Rights: (C) 2010 European Society of Cardiology
RMID: 0020095360
DOI: 10.1097/HJR.0b013e32832f3b56
Appears in Collections:Public Health publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.